SEC Tracker
Get the app

Compass Therapeutics CMPX

CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel

Form
8-K
Filed
Period
Importance
Routine
Document
8-K
Exhibit 99.1
Press release
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Compass Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Ocugen OCGN public float $279M, Jun 30, 2025
  2. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  3. Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025
  4. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  5. Standard Biotools LAB public float $291M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.